MDS Virtual Congress 2021

September 17-22, 2021. Virtual Congress. www.mdscongress.org

View by Title View Categories

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Comparison of Antiparkinsonian Medication Initiation and Levodopa-Equivalent Daily Dose Across PPMI, STEADY-PD III, and SURE-PD3

J. Chan, N. Hanan, J. Lowell, M. Kostrzebski, D. Penz, C. Tarolli, T. Mestre, A. Lutz, C. Lungu, C. Coffey, D. Oakes, M. Schwarzschild, T. Simuni, E. Macklin (Boston, USA)
Comparison of correlations of structural magnetic resonance imaging measures with smartphone-based active tests and clinical tests in Huntington’s disease

J. Rennig, D. Hawellek, J. Dorn, F. Lipsmeier, S. Holiga, C. Simillion, S. Schobel, M. Lindemann (Basel, Switzerland)
COMPARISON OF ELECTROPHYSIOLOGIC AND ULTRASOUND GUIDANCE FOR ONABOTULINUM TOXIN-A INJECTIONS IN FOCAL UPPER EXTREMITY SPASTICITY AND DYSTONIA

C. Lungu, A. Nmashie, MC. George, T. Wu, S. Shin, B. Karp, E. Considine, W. Tse, S. Frucht, C. Wu, V. Koo, G. Norato, K. Alter, M. Hallet, DM. Simpson ()
COMPARISON OF FREQUENCY, CLINICAL PROFILE AND ETIOLOGIES OF PARKINSONISM IN 2008 AND 10 YEARS LATER AT THE NEUROLOGY DEPARTMENT OF BEFELATANANA UNIVERSITY TEACHING HOSPITAL, ANTANANARIVO, MADAGASCAR

NF. Rasaholiarison, M. Ratsimandresy, JL. Rakotomanana, A. Tehindrazanarivelo (Fianarantsoa, Madagascar)
Comparison of gastrointestinal transit times in typical and erratic levodopa-responders in patients with Parkinson’s disease.

D. Safarpour, B. Brumbach, M. Arena, J. Quinn, J. Nutt, R. Pfeiffer (Portalnd, USA)
Comparison of pre – and post – clinical outcomes after COVID-19 lockdown in people with Parkinson’s in Portugal

C. Godinho, D. Tavares, J. Dean, J. Domingos (Sintra, Portugal)
Comparison of video-instructed and operator-instructed markerless motion analysis with clinical rating-scales in patients with Parkinson’s Disease

J. Bendig, H. Röhling, J. Leidig, A. Spanz, A. Frank, K. Loewenbrück, K. Otte, B. Falkenburger (Dresden, Germany)
Comparisons Between Parkinson’s Disease Patients and At-Risk Individuals: Can Olfactory Deficits and Cognitive Measures Serve as Preclinical Markers?

L. Pimer, J. Fisk, M. Khan, R. Mckelvey, H. Robertson, T. Rolheiser, K. Schoffer, K. Good (Halifax, Canada)
Compensation strategies for gait impairment in Parkinson’s disease: a survey among 4,324 patients

A. Tosserams, L. Wit, I. Sturkenboom, M. Nijkrake, B. Bloem, J. Nonnekes (Nijmegen, Netherlands)
Compensatory functional mechanisms of response inhibition in Parkinson’s Disease with impulse control disorders

T. Esteban-Peñalba, P. Paz-Alonso, I. Navalpotro-Gomez, M. Rodriguez-Oroz (Donostia, Spain)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z